Q-omics provides the consensus-scored ZNF567 profile across patient tissues and cancer cell-line models. ZNF567 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF567 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ZNF567 RNA expression shows 20,962 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, THCA, and KIRP as cancer lineages where ZNF567 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF567 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF567 survival associations across molecular data types. ZNF567 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF567 RNA expression–survival associations across cancer types. High ZNF567 expression shows unfavorable associations in LGG, MESO and KIRP, but favorable associations in UCS, KIRC and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF567 RNA expression.
This table summarizes ZNF567 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF567. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF567 shows lower tumor expression in THCA and KICH and higher tumor expression in LUAD, LIHC, BLCA and CHOL. The THCA box plot shows higher ZNF567 RNA expression in normal versus tumor tissue (log2 FC = −0.478, t-test p < 0.001).
This table shows molecular features associated with ZNF567 in patient tissues and cancer cell lines. In patient samples, ZNF567 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF567 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
